Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies

Blood (2022) 140 (Supplement 1): 6436–6438.

https://doi.org/10.1182/blood-2022-163235

Published: 2022

Journal Articles

The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results

David A Sallman, MD, Adam S. Asch, MD, Monzr M. Al Malki, MD, Daniel J. Lee, MD, William B. Donnellan, MD, Guido Marcucci, MD, Suman Kambhampati, MD, Naval G. Daver, MD, Guillermo Garcia-Manero, MD, Rami S. Komrokji, MD, Joanna Van Elk, Ming Lin, PhD, Jens-Peter Volkmer, MD, Chris H Takimoto, MD PhD, Mark Chao, MD PhD, Paresh Vyas, MD PhD

Blood (2019) 134 (Supplement_1): 569.

https://doi.org/10.1182/blood-2019-126271

Published: 2019

Journal Articles

An All Antibody Approach for Conditioning Bone Marrow for Hematopoietic Stem Cell Transplantation with Anti-cKIT and Anti-CD47 in Non-Human Primates

Kristopher D Marjon, PhD, James Y Chen, MD PhD, Jiaqi Duan, MS, Timothy S Choi, BS, Kavitha Sompalli, MS, Dongdong Feng, PhD, Ofelia Mata, Sharline Chen, B.S., Leslie Kean, MD PhD, Mwe Mwe Chao, MD, Mark Chao, MD PhD, Chris H Takimoto, MD PhD, Balaji Agoram, PhD, Cynthia E. Dunbar, MD, Ravi Majeti, MD PhD, Irving L Weissman, MD, Jie Liu, PhD MD, Jens-Peter Volkmer, MD

Blood (2019) 134 (Supplement_1): 4428.

https://doi.org/10.1182/blood-2019-131490

Published: 2019

Journal Articles

Translational Study of Cell Surface Proteins in Non-Hodgkin Lymphoma Patients Treated with the First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Rituximab

Roy Louis Maute, PhD, James Y Chen, MD PhD, Kristopher David Marjon, PhD, Jiaqi Duan, MS, Timothy Choi, BA, Mark Chao, MD PhD, Chris H Takimoto, MD PhD, Balaji Agoram, PhD, Jens-Peter Volkmer, MD

Blood (2019) 134 (Supplement_1): 5229.

https://doi.org/10.1182/blood-2019-127526

Published: 2019

Journal Articles

Combination Treatment with 5F9 and Azacitidine Enhances Phagocytic Elimination of Acute Myeloid Leukemia

Dongdong Feng, PhD, Phung Gip, PhD, Kelly Marie McKenna, BS, Feifei Zhao, Ofelia Mata, Timothy S Choi, BS, Jiaqi Duan, MS, Kavitha Sompalli, MS, Ravi Majeti, MD PhD, Irving L Weissman, MD, Chris H Takimoto, MD PhD, Mark Ping Chao, MD PhD, James Y Chen, MD PhD, Jie Liu, PhD MD, Jens-Peter Volkmer, MD

Blood (2018) 132 (Supplement 1): 2729.

https://doi.org/10.1182/blood-2018-99-120170

Published: 2018

Journal Articles

RBC-Specific CD47 Pruning Confers Protection and Underlies the Transient Anemia in Patients Treated with Anti-CD47 Antibody 5F9

James Y Chen, MD PhD, Kelly Marie McKenna, BS, Timothy S Choi, BS, Jiaqi Duan, MS, Lynette Brown, MSc, Jennifer J Stewart, PhD, Kavitha Sompalli, MS, Paresh Vyas, Stanley Schrier, MD, Ravindra Majeti, MD PhD, Irving L Weissman, MD, Kyle Elrod, BS, Mark Ping Chao, MD PhD, Chris H Takimoto, MD PhD, Jie Liu, PhD MD, Jens-Peter Volkmer, MD

Blood (2018) 132 (Supplement 1): 2327.

https://doi.org/10.1182/blood-2018-99-115674

Published: 2018

Journal Articles

Pharmacokinetics and Safety of Bortezomib In Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Results of the Phase 1 National Cancer Institute Organ Dysfunction Working Group Study NCI 6432

Karthik Venkatakrishnan, Ramesh K Ramanathan, John Sarantopoulos, Daniel L Mulkerin, Stephen I Shibata, Anne Hamilton, Afshin Dowlati, Sridhar Mani, Michelle A Rudek, Percy Ivy, Chris H Takimoto, Rachel Neuwirth, Sudha Parasuraman, Patricia M LoRusso

Blood (2010) 116 (21): 3975.

https://doi.org/10.1182/blood.V116.21.3975.3975

Published: 2010

NARROW

Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies

The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results

An All Antibody Approach for Conditioning Bone Marrow for Hematopoietic Stem Cell Transplantation with Anti-cKIT and Anti-CD47 in Non-Human Primates

Translational Study of Cell Surface Proteins in Non-Hodgkin Lymphoma Patients Treated with the First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Rituximab

Combination Treatment with 5F9 and Azacitidine Enhances Phagocytic Elimination of Acute Myeloid Leukemia

RBC-Specific CD47 Pruning Confers Protection and Underlies the Transient Anemia in Patients Treated with Anti-CD47 Antibody 5F9

Pharmacokinetics and Safety of Bortezomib In Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Results of the Phase 1 National Cancer Institute Organ Dysfunction Working Group Study NCI 6432

Email alerts

ASH Publications

American Society of Hematology

Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies

The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results

An All Antibody Approach for Conditioning Bone Marrow for Hematopoietic Stem Cell Transplantation with Anti-cKIT and Anti-CD47 in Non-Human Primates

Translational Study of Cell Surface Proteins in Non-Hodgkin Lymphoma Patients Treated with the First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Rituximab

Combination Treatment with 5F9 and Azacitidine Enhances Phagocytic Elimination of Acute Myeloid Leukemia

RBC-Specific CD47 Pruning Confers Protection and Underlies the Transient Anemia in Patients Treated with Anti-CD47 Antibody 5F9

Pharmacokinetics and Safety of Bortezomib In Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Results of the Phase 1 National Cancer Institute Organ Dysfunction Working Group Study NCI 6432

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only